Therapeutic effect of soluble factors of M2 phenotype macrophages in children with language impairments

The aim of the present study was to assess safety and clinical efficacy of inhalation immunotherapy based on intranasal administration of bioactive factors produced by the M2 phenotype macrophages in children with language impairments, as well as to study the effect of inhalation immunotherapy on the cytokine profile in the patients' blood serum. The study was carried out according to the NCT04689282 protocol (www.ClinicalTrials.gov) and included 14 children (9 boys / 5 girls), aged 3 to 8 years, with language impairments associated with perinatal or postnatal CNS lesions of various origin. The children recruited into the study were assessed by a neurologist and speech therapist before the therapy, at the end of the course (1 month), and 6 months later. Serum samples for cytokine analysis were obtained before and 1 month after therapy. The course of intranasal inhalations by the conditioned M2 media (2 ml one time per day for 28-30 days) was safe and well tolerated. None of the 14 treated children had significant adverse reactions and severe undesirable events. Intranasal immunotherapy led to a decrease in the severity of language problems, which manifested by improved speech understanding by 45%; the sensorimotor level of speech, by 51%; word formation skills, by 72%, as well as a twofold increase in general and fine motor skills. In children with signs of autism spectrum disorders, along with a language improvement, a decrease in the severity of autistic symptoms was registered, as evidenced by statistically significant decrease in the CARS score from 42.5 to 38.5 after 1 month, and to 33 points after 6 months (p < 0.05). The clinical effect was revealed rather soon, i.e., within a month after the first procedure, being maintained or intensified during a follow-up for 6 months. At the same time, two-thirds of the children showed a clear clinical improvement, with insignificant effect in the rest of patients. Comparative analysis of the serum cytokine levels in these subgroups showed that children with a pronounced positive response to inhaled immunotherapy differed in the following parameters: (1) initially higher level of VEGF and IGF-1, and (2) decrease the level of TNFα in response to intranasal immunotherapy. In summary, we first tested a fundamentally new approach based on the use of soluble factors from M2-type macrophages and intranasal route of their administration in order to treat the children with severe language impairments, demonstrating safety and obtained preliminary data on effectiveness of such approach.

1. Badalyan L.O. Pediatric neurology. Moscow: MEDpress-inform, 2019, 608 p.

2. Kornev A.N. Fundamentals of childhood speech pathology: clinical and psychological aspects. St. Petersburg: Rech, 2006. 380 p.

3. Fotekova T.A. Test method for the diagnosis of oral speech in primary schoolchildren. Moscow: ARKTM, 2000. 55 p.

4. Shevela E.Ya., Sakhno L.V., Kafanova M.Yu., Davydova M.N., Andrushkevich M.M., Ostanin A.A., Chernykh E.R. A method of obtaining a conditioned medium with a regenerative potential for intranasal administration in the treatment of diseases of the central nervous system / Patent RF, no. 2016121776, app. 01.06.2016.

5. Alcala-Barraza S.R., Lee M.S., Hanson L.R., McDonald A.A., Frey WH. 2nd, McLoon L.K. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target., 2010, Vol. 18, no. 3, pp. 179-190.

6. Bajnok A., Berta L., Orban C., Veres G., Zadori D., Barta H., Meder U., Vecsei L., Tulassay T., Szabo M., Toldi G. Distinct cytokine patterns may regulate the severity of neonatal asphyxia-an observational study. J. Neuroinflammation, 2017, Vol. 14, no. 1, 244. doi:10.1186/s12974-017-1023-2.

7. Benedict C., Kern W., Schultes B., Born J., Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J. Clin. Endocrinol. Metab., 2008, Vol. 93, pp. 1339-1344.

8. Bonneau D., Verny C., Uze J. Genetics of specific language impairments. Arch. Pediatr., 2004, Vol. 11, no. 10, pp. 1213-1216. (In French)

9. Chernykh E.R., Shevela E.Y., Sakhno L.V., Tikhonova M.A., Petrovsky Y.L., Ostanin A.A. The generation and properties of human M2-like macrophages: potential candidates for CNS repair? Cell. Therapy Transpl., 2010, Vol. 2, no 6, pp. 1-7.

10. di Marco B., Bonaccorso C.M., Aloisi E., d'Antoni S., Catania M.V. Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: a neuro-immune perspective. CNS Neurol. Disord. Drug Targets, 2016, Vol. 15, no. 4, pp. 448-463.

11. Dhuria S.V., Hanson L.R., Frey W.H. 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci., 2010, Vol. 99, no. 4, pp. 1654-1673.

12. Emanuele E., Orsi P., Barale F., diNemi S.U., Bertona M., Politi P. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism. Clin. Biochem., 2010, Vol. 43, pp. 317-319.

13. Ferguson B.J., Marler S., Altstein L.L., Lee E.B., Mazurek M.O., McLaughlin A., Macklin E.A., McDonnell E., Davis D.J., Belenchia A.M., Gillespie C.H., Peterson C.A., Bauman M.L., Margolis K.G., Veenstra-VanderWeele J., Beversdorf D.Q. Associations between cytokines, endocrine stress response, and gastrointestinal symptoms in autism spectrum disorder. Brain Behav. Immun., 2016, Vol. 58, pp. 57-62.

14. Hallschmid M., Benedict C., Schultes B., Born J., Kern W. Obese men respond to cognitive but not to catabolis brain insulin signaling. Int. J. Obes. (Lond.), 2008, Vol. 32, pp. 275-282.

15. Hanson L.R., Frey W.H. 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci., 2008, Vol. 9, Suppl. 3, S5. doi:10.1186/1471-2202-9-S3-S5.

16. Jin K., Wang X., Xie L., Mao X.O., Zhu W., Wang Y., Shen J., Mao Y., Banwait S., Greenberg D.A. Evidence for stroke-induced neurogenesis in the human brain. Proc. Natl Acad. Sci. USA, 2006, Vol. 103, pp. 13198-13202.

17. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl Acad. Sci. USA, 2002, Vol. 99, pp. 11946-11950.

18. Kempuraj D., Thangavel R., Natteru P.A., Selvakumar G.P., Saeed D., Zahoor H., Zaheer S., Iyer S.S., Zaheer A. Neuroinflammation induces neurodegeneration. J. Neurol. Neurosurg. Spine, 2016, Vol. 1, no. 1, 1003.

19. Lambrechts D., Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim. Biophys. Acta, 2006, Vol. 1762, pp. 1109-1121.

20. Lange C., Storkebaum E., de Almodovar C.R., Dewerchin M., Carmeliet P. Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat. Rev. Neurol., 2016, Vol. 12, pp. 439-454.

21. Liu S.H., Shi X.J., Fan F.C., Cheng Y. Peripheral blood neurotrophic factor levels in children with autism spectrum disorder: a meta-analysis. Sci. Rep., 2021, Vol. 11, no. 1, 15. doi: 10.1038/s41598-020-79080-w.

22. Liu X.F., Fawcett J.R., Thorne R.G., DeFor T.A., Frey W.H. 2nd. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci., 2001, Vol. 187, no. 1-2, pp. 91-97.

23. Louissaint A.Jr., Rao S., Leventhal C., Goldman S.A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron, 2002, Vol. 34, no. 6, pp. 945-960.

24. Madathil S.K., Evans H.N., Saatman K.E. Temporal and regional changes in IGF-1/IGF-1R signaling in the mouse brain after traumatic brain injury. J. Neurotrauma, 2010, Vol. 27, pp. 95-107.

25. Masi A., Breen E.J., Alvares G.A., Glozier N., Hickie I.B., Hunt A., Hui J., Beilby J., Ravine D., Wray J., Whitehouse A.J.O., Guastella A.J. Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder. Mol. Autism, 2017, Vol. 8, 63. doi: 10.1186/s13229-017-0176-2.

26. Mason J.L., Xuan S., Dragatsis I., Efstratiadis A., Goldman J.E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci., 2003, Vol. 23, no. 20, pp. 7710-7718.

27. McAdams R.M., Juul S.E. The role of cytokines and inflammatory cells in perinatal brain injury. Neurol. Res. Int., 2012, Vol. 2012, 561494. doi:10.1155/2012/561494.

28. Nicoletti J.N., Shah S.K., McCloskey D.P., Goodman J.H., Elkady A., Atassi H., Hylton D., Rudge J.S., Scharfman H.E., Croll S.D. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience, 2008, Vol. 151, no. 1, pp. 232-241.

29. Nishibe M., Barbay S., Guggenmos D., Nudo R.J. Reorganization of motor cortex after controlled cortical impact in rats and implications for functional recovery. J. Neurotrauma, 2010, Vol. 27, no. 12, pp. 2221-2232.

30. Olmos G., Llado J. Tumour necrosis factor alpha: A link between neuroinflammation and excitotoxicity. Mediators Inflamm., 2014, Vol. 2014, 861231. doi: 10.1155/2014/861231

31. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., van den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxiaresponse element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet., 2001, Vol. 28, no. 2, pp. 131-138.

32. Pasqualetti G., Brooks D.J., Edison P. The role of neuroinflammation in dementias. Curr. Neurol. Neurosci. Rep., 2015, Vol. 15, no. 4, 17. doi: 10.1007/s11910-015-0531-7.

33. Sakhno L.V., Shevela E.Y., Tikhonova M.A., Ostanin A.A., Chernykh E.R. The phenotypic and functional features of human M2 macrophages generated under low serum conditions. Scand. J. Immunol., 2016, Vol. 83, no. 2, pp. 151-159.

34. Shohami E., Bass R., Wallach D., Yamin A., Gallily R. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J. Cereb. Blood Flow Metab., 1996, Vol. 16, no. 3, pp. 378-384.

35. Silveira R.C., Procianoy R.S. Interleukin-6 and tumor necrosis factor-alpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. J. Pediatr., 2003, Vol. 143, no. 5, pp. 625-629.

36. Şimşek F., Işık Ü., Aktepe E., Kılıç F., Şirin F.B., Bozkurt M. Comparison of serum VEGF, IGF-1, and HIF-1a levels in children with autism spectrum disorder and healthy controls. J. Autism Dev. Disord., 2021. doi:10.1007/s10803-020-04820-w.

37. Skaper S.D., Facci L., Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol. Disord. Drug Targets, 2014, Vol. 13, no. 10, pp. 1654-1066.

38. Spetter M.S., Hallschmid М. Intranasal neuropeptide administration to target the human brain in health and disease. Mol. Pharm., 2015, Vol. 12, no. 8, pp. 2767-2780.

39. Sun Y., Jin K., Xie L., Childs J., Mao X.O., Logvinova A., Greenberg D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest., 2003, Vol. 111, no. 12, pp. 1843-1851.

40. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. 2nd. Delivery of IGF-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 2004, Vol. 127, pp. 481-496.

41. Torun Y.T., Guney E., Aral A., Buyukta§kin D., Tunca H., Taner Y.I., i§eri E. Determination of serum vascular endothelial growth factor levels in attention deficit hyperactivity disorder: A case control study. Clin. Psychopharmacol. Neurosci., 2019, Vol. 17, no. 4, pp. 517-522.

42. Xie J., Huang L., Li X., Li H., Zhou Y., Zhu H., Pan T., Kendrick K.M., Xu W. Immunological cytokine profiling identifies TNF-a as a key molecule dysregulated in autistic children. Oncotarget, 2017, Vol. 8, no. 47, pp. 82390-82398.

43. Xiong Y., Mahmood A., Chopp M. Angiogenesis, neurogenesis and brain recovery of function following injury. Curr. Opin. Investig. Drugs, 2010, Vol. 11, no. 3, pp. 298-308.

44. Xu N., Li X., Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm., 2015, Vol. 2015, 531518. doi: 10.1155/2015/531518.

45. Zhao Y., Xiao W., Chen K., Zhan Q., Ye F., Tang X., Zhang X. Neurocognition and social cognition in remitted first-episode schizophrenia: correlation with VEGF serum levels. BMC Psychiatry, 2019, Vol. 19, no. 1, 403. doi: 10.1186/s12888-019-2397-8.

46. Zhu Y., Jin K., Mao X.O., Greenberg D.A. Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. FASEB J., 2003, Vol. 17, no. 2, pp. 186-193.

47. Zhu J., Jiang Y., Xu G., Liu X. Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors. Histol. Histopathol., 2012, Vol. 27, no. 5, pp. 537-548.